IMR Press / EJGO / Volume 30 / Issue 5 / pii/2009143

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Case Report

Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer

Show Less
1 Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka (Japan)
Eur. J. Gynaecol. Oncol. 2009, 30(5), 583–585;
Published: 10 October 2009
Abstract

Paclitaxel and carboplatin combination chemotherapy (TC) is increasingly performed in ovarian cancer patients undergoing hemodialysis. However, appropriate dosage and time interval between the end of carboplatin administration and the initiation of hemodialysis remain unclear. We performed TC in a hemodialysis patient with ovarian cancer. Paclitaxel was administered at 150 mg/m2 for 3 h, followed by administration of 125 mg of carboplatin within 30 min to achieve a target area under the concentration/time curve (AUC) of 5.0 mg/ml·min by Calvert’s formula. At 1 h after completing carboplatin administration, hemodialysis was performed for 4 h. Pharmacokinetic analysis showed we had achieved the desired serum concentration of paclitaxel. However, AUC of free platinum was very low (AUC = 0.98 mg/ml·min). Although the appropriate time interval between the end of carboplatin administration and the initiation of hemodialysis remains a controversial issue, our findings suggest that an interval of at least 1 h is required. 

Keywords
Paclitaxel
Carboplatin
Pharmacokinetics
Ovarian cancer
Hemodialysis
Share
Back to top